Application of CGE in cell and gene therapy by Kerstin Pohl | Mar 12, 2025 | Biopharma, BioPhase 8800 system, BlogsRead time: 10 minutes In a recent webinar, available on demand, the scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data...
The whys behind the dos and don’ts of oligonucleotide analysis by Kerstin Pohl | Feb 1, 2025 | Biopharma, Blogs, PharmaWe know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this...
Plasmid manufacturing: Setting up your CGT programs for success by Kerstin Pohl | Nov 15, 2024 | Biopharma, BioPhase 8800 system, Blogs, PA 800 systemRead time: 5 minutes Plasmid DNA serves a variety of purposes, from critical starting material for proteins, mRNA, viral vectors, and drug substances. Below, Dr. Emma Bjorgum, the Vice President of Client Services of the DNA Business Unit at Aldevron and an expert in...
Pure and simple: Understanding LNP analytics for better mRNA-based drugs by Kerstin Pohl | Jul 3, 2024 | Biopharma, Blogs, ZenoTOF 7600 systemRead time: 11 minutes Interviewee: Adam Crowe (PhD), Sr Manager of Analytical Development, Cytiva A few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of...
Discover high-quality mRNA integrity and purity assessments by Kerstin Pohl | May 22, 2024 | Biopharma, BioPhase 8800 system, BlogsRead time: 8 minutes Lipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA (mRNA) products or other drug substances. In a recent webinar, Jérémie Parot (PhD), Research Scientist at SINTEF Industry, demonstrated the robust and...
Addressing stability challenges of mRNA-LNP therapies by Kerstin Pohl | May 13, 2024 | Biopharma, BioPhase 8800 system, BlogsRead time: 6 minutes In a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products. In the...
A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics by Kerstin Pohl | Apr 29, 2024 | Biopharma, Blogs, Pharma, QTOF, QTRAP / Triple Quad, ZenoTOF 7600 systemRead time: 10 minutes In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since...
Supporting new CRISPR gene editing systems by Kerstin Pohl | Apr 17, 2024 | Biopharma, Blogs, PA 800 systemRead time: 7 minutes Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of...
A new approach for comprehensive AAV evaluation including full and empty analysis by Kerstin Pohl | Apr 16, 2024 | Biopharma, BioPhase 8800 system, BlogsRead time: 6 minutes Certain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well...
Better mRNA-LNPs: encapsulation efficiency, mRNA integrity and purity, lipid N-oxides and beyond by Kerstin Pohl | Mar 14, 2024 | Biopharma, BioPhase 8800 system, Blogs, ZenoTOF 7600 systemRead Time: 7 minutes Interviewee: Jane Luo (PhD), Senior Scientist, SCIEX Lipid nanoparticles (LNPs) are widely used vehicles for mRNA-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause...
Adducts and N-oxides: understanding lipid nanoparticles (LNPs) for better mRNA drugs by Kerstin Pohl | Feb 20, 2024 | Biopharma, Blogs, ZenoTOF 7600 systemRead Time: 9 minutes Lipid nanoparticles (LNPs) are widely used vehicles for messenger RNA (mRNA)-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause functional loss of the mRNA cargo. In a...
Beyond mRNA: how advances in analytical techniques are enabling a revolution in the RNA drug landscape by Kerstin Pohl | Nov 7, 2023 | Biopharma, Blogs, PA 800 systemRead time: 9 minutes Currently, there are 3 main types of in vitro transcribed (IVT) RNA drugs, encapsulated in lipid nanoparticles (LNPs). Two of these—conventional messenger RNA (mRNA) and base-modified mRNA (bmRNA), which incorporates chemically modified...